Mesa Laboratories, Inc. (MLAB) Earnings
Mesa Laboratories, Inc. is expected to report next earnings on November 5, 2026 (in NaN days), with a consensus EPS estimate of $1.59. MLAB has beaten EPS estimates in 9 of its last 12 reported quarters (average surprise +18.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 10, 2026 | $2.63 | $2.68 | +1.9% | $60M | -1.2% |
| May 27, 2026 | $2.09 | $2.76 | +32.1% | $64M | -2.3% |
| Feb 3, 2026 | $2.41 | $3.07 | +27.4% | $65M | -0.1% |
| Nov 6, 2025 | $1.56 | $1.76 | +12.8% | $61M | -0.5% |
| May 28, 2025 | $2.75 | $2.23 | -18.9% | $62M | +0.4% |
| Feb 4, 2025 | $1.41 | $2.67 | +89.4% | $63M | +2.1% |
| Nov 7, 2024 | $2.48 | $2.45 | -1.2% | $58M | -0.1% |
| Jun 5, 2024 | $-0.11 | $2.77 | +2618.2% | $59M | +6.6% |
| Aug 3, 2023 | $1.67 | $1.77 | +6.2% | $51M | -3.1% |
| May 25, 2023 | $2.00 | $1.94 | -3.0% | $56M | -5.0% |
| Feb 6, 2023 | $2.09 | $2.35 | +12.5% | $54M | -7.1% |
| Nov 3, 2022 | $1.40 | $2.88 | +105.7% | $59M | +10.5% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · August 10, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
New CEO Overview and Strategic Direction - New CEO Siddhartha Kadia completed a 100-day review of the business, concluding Mesa has durable, regulation-embedded high-margin franchises with growing earnings power, all problems are fixable execution issues, not demand or structural issues. - Near-term strategic priority is organic execution of existing businesses and disciplined capital reallocation to high-return, high-growth segments, rather than large acquisitions; small tuck-in or distributor buyouts may occur later in the year. - CEO has personally visited all large sites, met over half of global employees, and engaged with key customers to install a growth mindset focused on building loyal customers. Operational Updates by Segment - SDC: The quarterly revenue decline is caused by delivery reliability issues, not weak demand. Past due backlog rose ~$1 million from its year-end low (still well below 2026 peaks) because prior improvements were episodic, not locked into standard processes. Fixing delivery reliability is the top operational priority; the SVP of Operations is singularly focused on reducing process variability and tightening cycle times without loosening quality standards. Underlying demand remains healthy, with 5% trailing 12-month revenue growth. - BPD: A new general manager has been installed to rebuild the commercial engine (sales processes, pipeline discipline, coverage), a process that will take most of a year to complete. R&D investment has been reprioritized to accelerate launch of the next-generation Gyrolab platform, now targeted for fiscal 2028, the first new Gyrolab launch since 2018. BPD returned to 5% YoY growth in Q1 after a 30% decline last quarter, partially driven by easier comparisons and catch-up on deferred orders from prior-year export control delays; the turnaround is not yet complete, but full-year growth is expected. - Clinical Genomics: The business continues to be managed deliberately with strict cost and return discipline, with no change to strategic posture. Financial and Balance Sheet Highlights - GAAP operating income increased 129% YoY to $7 million; non-GAAP adjusted operating income increased 16.5% to $15 million (19.5% excluding a $382,000 legal settlement). - Operating cash flow increased $12.8 million YoY to $14.7 million, driven by stronger collections and improved operating performance. - $8.7 million of debt was repaid in the quarter, bringing the net leverage ratio to 1.85x. The target is to reduce leverage to 1.5x-1.75x by the end of fiscal 2027. - Q1 is structurally the lowest-volume quarter, and the strong Q1 margin result should not be annualized; a portion of operating leverage will be reinvested in faster-growing, higher-return segments to accelerate growth this year.
Guidance
- Full-year fiscal 2027 guidance will be released alongside first half 2027 results at the November 2027 earnings call, in line with the prior commitment. Management declined to provide specific full-year guidance ahead of that date to ensure the forecast is informed by a full half year of operating data under new leadership. - Q1 2027 trends are consistent with internal plans, and the company returned to positive core organic growth in Q1 as previously expected in May. - The company confirms it will continue deleveraging to reach a net leverage ratio of 1.5x to 1.75x by the end of fiscal 2027. - There is a reasonable possibility of a favorable impact to the effective tax rate within the next 12 months from a potential partial release of the U.S. valuation allowance, though timing and amount remain uncertain.
Segment performance
1. SDC (Sterilization and Disinfection Controls): Reported Q1 2027 revenue of $24.5 million, a 3.6% organic year-over-year decline, contributing 41% of total consolidated revenue. Trailing 12-month revenue is ~$101 million, up 5% year-over-year; fiscal 2026 revenue was $101.6 million, up from $93.4 million in fiscal 2025. Gross profit margin decreased 150 basis points due to volume effects from delivery timing issues on a partially fixed cost base. 2. BPD (Biopharmaceutical Development): Q1 2027 revenue of $12.1 million, 5% organic year-over-year growth. Gross profit margin increased 800 basis points, driven by a higher mix of high-margin immunoassay consumables, supply chain efficiencies, and operating leverage from revenue growth. 3. Calibration Solutions: Q1 2027 revenue of $13.3 million, 7.6% organic year-over-year growth. Gross profit margin increased 350 basis points, driven by higher revenue on a partially fixed cost base. 4. Clinical Genomics: Q1 2027 revenue of $10.3 million, essentially flat (-0.1% organic year-over-year). China revenue declined 7% (a slower pace of decline than prior year), while non-China revenue grew 0.6%. Gross profit margin increased 790 basis points from price improvements and manufacturing/supply chain efficiencies. Consolidated total Q1 2027 revenue was $60.1 million, up 1% year-over-year, with 0.4% core organic growth after excluding currency translation impacts.
Risks & headwinds
- Extended delivery delays for SDC products could lead customers to evaluate alternative suppliers, creating a risk of permanent lost demand. - Unrealized currency gains/losses on an outstanding intercompany loan will continue to create quarter-to-quarter volatility in nonoperating expense. - The final impact and timing of the potential U.S. valuation allowance partial release remains uncertain, dependent on ongoing assessment and other factors including jurisdictional income mix and discrete items. - Forward-looking statements (including launch timelines, margin targets, and deleveraging goals) are subject to risks including: market acceptance of new products, ability to execute operational and strategic initiatives, manufacturing/fulfillment/supply chain performance, changes in customer purchasing patterns, new product development success, regulatory matters, global and national economic conditions, and changes in expected tax rates.
Analyst Q&A
Q: Historically Mesa has focused on M&A. Which core business segments are the highest priority for capital and focus going forward?
A: Management is reallocating capital and management mindshare to SDC, BPD, and Calibration Solutions, the three core franchises with strong margin and growth profiles. Portfolio evaluation continues, and the company will provide more details when ready in November.
Q: What is the current state of liquidity and leverage, and what is the target leverage range?
A: Net leverage is currently 1.85x, with an effective interest rate of 5.6%. The target remains to reduce leverage to between 1.5x and 1.75x by the end of the fiscal year.
Q: Have conditions in China's clinical genomics market improved? What is Mesa's current exposure?
A: The China market still faces structural headwinds, but Mesa's exposure has declined significantly over the past two years, and China revenue now makes up a very small portion of overall company revenue.
Q: What are the top priorities for execution fixes following the 100-day review?
A: First, leadership changes have already been made where needed (such as the new BPD general manager), and senior operations leadership is singularly focused on fixing SDC's delivery issues. Second, management is building a culture of urgency and disciplined capital allocation, adding a growth mindset focused on customer loyalty without overhauling the existing strong quality culture.